IL236310A0 - New cabergoline history - Google Patents

New cabergoline history

Info

Publication number
IL236310A0
IL236310A0 IL236310A IL23631014A IL236310A0 IL 236310 A0 IL236310 A0 IL 236310A0 IL 236310 A IL236310 A IL 236310A IL 23631014 A IL23631014 A IL 23631014A IL 236310 A0 IL236310 A0 IL 236310A0
Authority
IL
Israel
Prior art keywords
derivatives
novel
novel cabergoline
cabergoline derivatives
cabergoline
Prior art date
Application number
IL236310A
Other languages
English (en)
Hebrew (he)
Original Assignee
Map Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Map Pharmaceuticals Inc filed Critical Map Pharmaceuticals Inc
Publication of IL236310A0 publication Critical patent/IL236310A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL236310A 2012-06-22 2014-12-17 New cabergoline history IL236310A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/043687 WO2013191704A1 (en) 2012-06-22 2012-06-22 Novel cabergoline derivatives

Publications (1)

Publication Number Publication Date
IL236310A0 true IL236310A0 (en) 2015-02-26

Family

ID=49769156

Family Applications (1)

Application Number Title Priority Date Filing Date
IL236310A IL236310A0 (en) 2012-06-22 2014-12-17 New cabergoline history

Country Status (11)

Country Link
EP (1) EP2863747A4 (zh)
JP (1) JP2015525239A (zh)
CN (1) CN104822264A (zh)
AU (1) AU2012382929A1 (zh)
BR (1) BR112014031945A2 (zh)
CA (1) CA2876321A1 (zh)
HK (1) HK1208997A1 (zh)
IL (1) IL236310A0 (zh)
RU (1) RU2014153672A (zh)
SG (1) SG11201408567PA (zh)
WO (1) WO2013191704A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107428745A (zh) * 2015-01-20 2017-12-01 Xoc制药股份有限公司 麦角灵化合物及其用途
CN106866656A (zh) * 2017-02-28 2017-06-20 西南交通大学 一类麦角碱衍生物及其在预防和治疗精神疾病的用途
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
DK338789A (da) * 1988-07-15 1990-01-16 Schering Ag 2-substituerede ergolinylurinstofderivater og fremgangsmaade til fremstilling deraf, deres anvendelse som laegemidler samt mellemprodukter til fremstilling deraf
DE3913756A1 (de) * 1989-04-21 1990-10-25 Schering Ag 8(beta)-substituierte ergoline, verfahren zu ihrer herstellung und ihre verwendung
WO1995005176A1 (en) * 1993-08-18 1995-02-23 Alcon Laboratories, Inc. Use of ergoline derivatives for the treatment of glaucoma
CZ287176B6 (cs) * 1997-10-03 2000-10-11 Galena A. S. Způsob přípravy ergolinových derivátů
JP2006516596A (ja) * 2003-02-05 2006-07-06 ファルマシア イタリア ソチエタ ペル アツィオニ 偏頭痛の予防治療のためのカベルゴリン
GB0307377D0 (en) * 2003-03-31 2003-05-07 Merad Pharmaceuticals Ltd Ergoline derivatives
HUP0400517A3 (en) * 2004-03-04 2006-05-29 Richter Gedeon Vegyeszet Process for producing cabergoline
WO2006097345A1 (en) * 2005-03-17 2006-09-21 Synthon Argentina S.A. Improved process for making cabergoline
GB0511060D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
EP2083008A1 (en) * 2007-12-07 2009-07-29 Axxonis Pharma AG Ergoline derivatives as selective radical scavengers for neurons
US20120095217A1 (en) * 2009-01-09 2012-04-19 Tobias Ritter Fluorine containing compounds and methods of use thereof
AR076300A1 (es) * 2009-04-15 2011-06-01 Astrazeneca Ab Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades.
EP2793583A4 (en) * 2011-12-21 2015-08-12 Map Pharmaceuticals Inc NOVEL NEUROMODULATORY CONNECTIONS

Also Published As

Publication number Publication date
AU2012382929A1 (en) 2015-02-05
CN104822264A (zh) 2015-08-05
SG11201408567PA (en) 2015-02-27
JP2015525239A (ja) 2015-09-03
WO2013191704A1 (en) 2013-12-27
HK1208997A1 (zh) 2016-03-24
EP2863747A4 (en) 2015-12-23
BR112014031945A2 (pt) 2017-06-27
CA2876321A1 (en) 2013-12-27
RU2014153672A (ru) 2016-08-10
EP2863747A1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
HUS2200040I1 (hu) Benzimidazol-prolin származékok
HK1206722A1 (zh) 新型雙環衍生物
HK1205740A1 (zh) 吡咯並三嗪酮衍生物
HK1205508A1 (zh) 新型雙環吡啶衍生物
ZA201502175B (en) Oxazolidin-2-one-pyrimidine derivatives
PT2838883T (pt) Novos derivados de fenil-tetra-hidroisoquinolina
IL239492A0 (en) New Matisergid Histories
HK1200824A1 (zh) 被取代的苯基唑衍生物
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
HK1208997A1 (zh) 新的卡麥角林衍生物
HK1208029A1 (zh) 咪唑並吡啶衍生物
HK1214244A1 (zh) 咪唑並吡啶衍生物